Last edition
News about "SETDB1 targeted cancer therapy"
Kazia Expands Oncology Platform with First-in-Class SETDB1 Inhibitor
Kazia Therapeutics expands its oncology platform with a first-in-class SETDB1 inhibitor, leveraging an AI-driven epigenetic drug discovery engine for faster and scalable candidate development.
SETDB1 Targeted Cancer Therapy | 15/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members